Timeline
REGN3479
A Regeneron-developed monoclonal antibody targeting Bundibugyo ebolavirus, now in the first authorised Bundibugyo treatment trial alongside MBP134.
2 of 2 entries (2 events, 0 interactions)
Filters
#11 16 Jul
Africa CDC: true cases up to 4x tally
Pandemics and Biosecurity#7 12 Jun